Wendan decoction in the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis

• Published in: Frontiers in pharmacology Vol. 13; p. 1039611
• Main Authors: Zhang, Yufeng, Liu, Ting, Zhang, Lianyue, Pu, Zhongping, Yan, Zheng, Hua, Haibing
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 17.10.2022
• Subjects: meta-analysis; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; Pharmacology; systematic review; wendan decoction
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2022.1039611

Introduction: The use of Wendan decoction (WDD) as a therapy for nonalcoholic fatty liver disease (NAFLD) has been studied in many clinical trials, and some of them showed that WDD is effective for treating this condition. However, no comprehensive research to evaluate the clinical efficacy of WDD in NAFLD patients had been performed. This systematic review and meta-analysis sought to provide an in-depth inquiry into the data currently available about the safety and effectiveness of WDD to treat NAFLD. Methods: We examined the primary database for any reports of randomized controlled trials (RCTs) including WDD and its effectiveness in treating NAFLD. We used the Jadad rating scale to determine the overall quality of the selected RCTs, and we searched the Cochrane Reviewer’s Handbook for criteria for potential bias. The primary findings from the included RCTs were recorded, and the meta-analysis was performed using RevMan5.4 software developed by the Cochrane Collaboration. Results: We retrieved ten RCTs that were suitable for this evaluation and included them in a systematic review and meta-analysis. The quality and risk of bias in the included RCTs were assessed. The meta-analysis showed that the total clinical effective rate was substantially greater in the WDD cohort compared with that in the control cohort, and liver function, blood lipid indices, and blood glucose-related indicators were substantially improved in the WDD-treated cohort compared with those in the control cohort. There was no significant difference in the incidence of adverse events between the two cohorts. Conclusion: WDD is safe and effective for treating NAFLD, which is advantageous for the patients’ liver function as well as their blood lipid indices and blood glucose-related indicators.